MX2010002317A - Derivados de indol sustituidos y metodos para su utilizacion. - Google Patents

Derivados de indol sustituidos y metodos para su utilizacion.

Info

Publication number
MX2010002317A
MX2010002317A MX2010002317A MX2010002317A MX2010002317A MX 2010002317 A MX2010002317 A MX 2010002317A MX 2010002317 A MX2010002317 A MX 2010002317A MX 2010002317 A MX2010002317 A MX 2010002317A MX 2010002317 A MX2010002317 A MX 2010002317A
Authority
MX
Mexico
Prior art keywords
substituted indole
methods
indole derivatives
derivatives
substituted
Prior art date
Application number
MX2010002317A
Other languages
English (en)
Inventor
Frank Bennett
Neng-Yang Shih
Srikanth Venkatraman
Tin-Yau Chan
Joseph A Kozlowski
F George Njoroge
Mousumi Sannigrahi
Kevin X Chen
Stuart B Rosenblum
Qingbei Zeng
Gopinadhan N Anilkumar
Jose S Duca
Francisco Velazquez
Charles A Lesburg
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39968138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010002317(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010002317A publication Critical patent/MX2010002317A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a derivados de indol sustituidos, composiciones que comprenden por lo menos un derivado de indol sustituido, y métodos para utilizar los derivados de indol sustituidos para tratar o prevenir una infección viral o un trastorno relacionado con un virus en un paciente.
MX2010002317A 2007-08-29 2008-08-27 Derivados de indol sustituidos y metodos para su utilizacion. MX2010002317A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96869807P 2007-08-29 2007-08-29
PCT/US2008/010148 WO2009032124A1 (en) 2007-08-29 2008-08-27 Substituted indole derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2010002317A true MX2010002317A (es) 2010-03-22

Family

ID=39968138

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002317A MX2010002317A (es) 2007-08-29 2008-08-27 Derivados de indol sustituidos y metodos para su utilizacion.

Country Status (17)

Country Link
US (1) US8614229B2 (es)
EP (1) EP2408761B1 (es)
JP (2) JP5272008B2 (es)
KR (1) KR20100067652A (es)
CN (1) CN101821252A (es)
AR (1) AR068106A1 (es)
AU (1) AU2008295484B2 (es)
BR (1) BRPI0815811A2 (es)
CA (1) CA2697454C (es)
CL (1) CL2008002539A1 (es)
EC (1) ECSP10010004A (es)
ES (1) ES2447543T3 (es)
MX (1) MX2010002317A (es)
PE (1) PE20090630A1 (es)
RU (1) RU2010111551A (es)
TW (1) TW200924780A (es)
WO (1) WO2009032124A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
CN101631773A (zh) 2006-12-22 2010-01-20 先灵公司 治疗或预防hcv和相关病毒感染的4,5-环化吲哚衍生物
AU2007339386B8 (en) 2006-12-22 2013-12-05 Merck Sharp & Dohme Corp. 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
WO2008136815A2 (en) 2006-12-22 2008-11-13 Schering Corporation 5, 6-ring annulated indole derivatives and use thereof
TW200911807A (en) * 2007-08-29 2009-03-16 Schering Corp 2,3-substituted azaindole derivatives and methods of use thereof
CN101821252A (zh) 2007-08-29 2010-09-01 先灵公司 取代的吲哚衍生物及其使用方法
JP5249344B2 (ja) * 2007-11-16 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション ヘテロ環の3位が置換されたインドール誘導体およびその使用
CA2705587A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
EP2303893B1 (en) * 2008-06-13 2016-12-07 Merck Sharp & Dohme Corp. Tricyclic indole derivatives
WO2010138791A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
EP2491033A4 (en) * 2009-10-20 2013-03-13 Eiger Biopharmaceuticals Inc AZAINDAZOLES FOR THE TREATMENT OF FLAVIVIRIDAE VIRUS INFECTION
WO2011061243A1 (en) * 2009-11-21 2011-05-26 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
PE20130062A1 (es) 2010-03-09 2013-02-28 Merck Sharp & Dohme Compuestos de sililo triciclicos fusionados para el tratamiento de enfermedades virales
RU2572558C2 (ru) * 2010-07-07 2016-01-20 Ф. Хоффманн-Ля Рош Аг Противовирусные гетероциклические соединения
CA2805440A1 (en) 2010-07-26 2012-02-09 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2012050848A1 (en) 2010-09-29 2012-04-19 Schering Corporation Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
CN103269586B (zh) 2010-10-26 2015-07-15 普雷西迪奥制药公司 丙型肝炎病毒抑制剂
MX2013006467A (es) 2010-12-09 2013-10-01 Amgen Inc Compuestos biciclicos como inhibidores pim.
JP2014510105A (ja) 2011-03-22 2014-04-24 アムジエン・インコーポレーテツド Pim阻害剤としてのアゾール化合物
JP2014515023A (ja) 2011-04-13 2014-06-26 メルク・シャープ・アンド・ドーム・コーポレーション 2’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2014059902A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
US9242988B2 (en) 2012-10-17 2016-01-26 Merck Sharp & Dohme Corp. 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
JP2016501200A (ja) 2012-11-19 2016-01-18 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. ウイルス性疾患を処置するための2−アルキニル置換ヌクレオシド誘導体
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9765107B2 (en) 2013-06-18 2017-09-19 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2014205592A1 (en) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof for treatment of hepatitis c
WO2014205593A1 (en) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
EP3313836B1 (en) 2015-06-26 2020-11-11 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
US10548899B2 (en) 2015-10-20 2020-02-04 Takeda Pharmaceutical Company Limited Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
EP3471737A4 (en) 2016-06-20 2019-12-25 Merck Sharp & Dohme Corp. CYCLIC PHOSPHONATE-SUBSTITUTED NUCLEOSIDE COMPOUND AND METHOD FOR USE THEREOF FOR TREATING VIRUS DISEASES
US20220281824A1 (en) * 2019-07-30 2022-09-08 Oregon State University Aryl hydrocarbon receptor activators

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE648639C (de) 1935-05-19 1937-08-05 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Dipyrrolen
US3632805A (en) * 1967-12-08 1972-01-04 Sumitomo Chemical Co Process for producing 1-aminoalkyl-benzodiazepine derivatives
DE2002208C3 (de) * 1969-01-25 1978-04-13 Sumitomo Chemical Co., Ltd., Osaka (Japan) 1 (Dialkylaminoacyl)-5-phenyl-7chlor-2,3-dihydro- IH-1,4-benzodiazepinderivate
JPS4945876B1 (es) 1970-01-29 1974-12-06
US3867372A (en) * 1970-02-03 1975-02-18 Sumitomo Chemical Co Benzodiazepine process
DE2141904B2 (de) * 1970-08-31 1976-07-01 Sumitomo Chemical Co., Ltd., Osaka (Japan) L- eckige klammer auf beta- (alpha'-tetrahydropyranyloxy)-aethyl eckige klammer zu -1,3-dihydro-5- phenyl-2h-1,4-benzodiazepin-2-one
JPS4843359B1 (es) * 1970-08-31 1973-12-18
JPS494461B1 (es) 1970-12-17 1974-02-01
AU575854B2 (en) * 1983-10-04 1988-08-11 Shionogi & Co., Ltd. 7beta-(carboxyalkenamido) cephalosporins
US5017380A (en) * 1986-07-02 1991-05-21 Shionogi & Co., Ltd. Gelatin hard capsule containing crystalline hydrate of oral cephalosporin
NZ220764A (en) 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
CA2038925A1 (en) 1990-03-26 1991-09-27 Takashi Sohda Indole derivatives, their production and use
JPH04149429A (ja) 1990-10-12 1992-05-22 Fuji Photo Film Co Ltd ハロゲン化銀カラー反転写真感光材料およびそれを用いた画像形成方法
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
BR9712544B1 (pt) 1996-10-18 2013-10-22 Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
FR2768146B1 (fr) 1997-09-05 2000-05-05 Oreal Nouveaux composes de la famille des indole-carboxyliques et leur utilisation
US20020164644A1 (en) 2000-04-05 2002-11-07 Ikuro Maruyama Adsorbents for high mobility group proteins and column for purifying body fluid
EP1268525B1 (en) * 2000-04-05 2008-12-31 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
AR030558A1 (es) * 2000-04-19 2003-08-27 Schering Corp COMPUESTOS MACROCICLICOS, QUE INCLUYEN ENANTIOMEROS, ESTEROISOMEROS, ROTAMEROS Y TAUTOMEROS, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES, COMPOSICIoN FARMACEUTICA, UN METODO PARA SU PREPARACION Y EL USO DE DICHOS COMPUESTOS PARA LA ELABORACION DE UN MEDICAMENTO, INHIBIDORES DE LA SERINA PROTEASA,
RU2003105221A (ru) * 2000-07-21 2004-09-20 Шеринг Корпорейшн (US) Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
AU2001276988B2 (en) 2000-07-21 2007-01-25 Dendreon Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
KR20030036917A (ko) 2000-10-10 2003-05-09 스미스클라인 비참 코포레이션 치환된 인돌, 이를 함유하는 약제학적 조성물, 및 이의PPAR-γ결합제로서의 용도
WO2002048172A2 (en) * 2000-12-12 2002-06-20 Schering Corporation Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
CA2430808A1 (en) * 2000-12-18 2002-06-27 Eli Lilly And Company Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
WO2002068412A1 (en) 2001-02-22 2002-09-06 School Of Pharmacy, University Of London Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
FR2839718B1 (fr) * 2002-05-17 2004-06-25 Sanofi Synthelabo Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant
JP2006505571A (ja) 2002-10-15 2006-02-16 リゲル ファーマシューテイカルズ、インコーポレイテッド 置換されたインドール及びhcv阻害剤としてのその使用
JP2004149429A (ja) 2002-10-29 2004-05-27 Takeda Chem Ind Ltd インドール化合物およびその用途
US20050075331A1 (en) * 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
NZ543897A (en) 2003-05-30 2009-04-30 Gemin X Pharmaceuticals Canada Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
GB0323845D0 (en) * 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
PE20090047A1 (es) * 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
NZ549223A (en) 2004-02-27 2010-10-29 Schering Corp Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
MXPA06009881A (es) 2004-03-01 2007-11-20 Viropharma Inc Derivados de piranoindol y el uso de los mismos para el tratamiento de infeccion o enfermedad de virus de hepatitis c.
AR049635A1 (es) * 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
WO2006034337A2 (en) 2004-09-23 2006-03-30 Wyeth Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus
DE102004047272A1 (de) * 2004-09-24 2006-04-06 Schering Ag Inhibitoren der löslichen Adenylatzyklase
JP2008517987A (ja) 2004-10-26 2008-05-29 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス薬としての四環式インドール誘導体
JP4149429B2 (ja) 2004-10-26 2008-09-10 本田技研工業株式会社 車両の走行安全装置
WO2006076529A1 (en) * 2005-01-14 2006-07-20 Genelabs Technologies, Inc. Indole derivatives for treating viral infections
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7482360B2 (en) 2005-09-23 2009-01-27 Schering Corporation Fused tetracyclic mGluR1 antagonists as therapeutic agents
WO2007084435A2 (en) 2006-01-13 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
PE20080197A1 (es) 2006-02-09 2008-04-11 Schering Corp Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s)
CN101631773A (zh) * 2006-12-22 2010-01-20 先灵公司 治疗或预防hcv和相关病毒感染的4,5-环化吲哚衍生物
WO2008136815A2 (en) * 2006-12-22 2008-11-13 Schering Corporation 5, 6-ring annulated indole derivatives and use thereof
AU2007339386B8 (en) * 2006-12-22 2013-12-05 Merck Sharp & Dohme Corp. 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
CN101821252A (zh) 2007-08-29 2010-09-01 先灵公司 取代的吲哚衍生物及其使用方法
TW200911807A (en) * 2007-08-29 2009-03-16 Schering Corp 2,3-substituted azaindole derivatives and methods of use thereof
BRPI0816116A2 (pt) * 2007-08-29 2015-03-03 Schering Corp Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
JP4737166B2 (ja) 2007-09-07 2011-07-27 株式会社デンソー 目詰まり検出装置
JP5249344B2 (ja) * 2007-11-16 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション ヘテロ環の3位が置換されたインドール誘導体およびその使用
CA2705587A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof

Also Published As

Publication number Publication date
AR068106A1 (es) 2009-11-04
AU2008295484B2 (en) 2013-09-26
JP2010537981A (ja) 2010-12-09
KR20100067652A (ko) 2010-06-21
TW200924780A (en) 2009-06-16
BRPI0815811A2 (pt) 2015-02-18
JP5272008B2 (ja) 2013-08-28
CA2697454C (en) 2015-11-03
CN101821252A (zh) 2010-09-01
CL2008002539A1 (es) 2009-07-17
JP2013100375A (ja) 2013-05-23
CA2697454A1 (en) 2009-03-12
US8614229B2 (en) 2013-12-24
EP2408761A1 (en) 2012-01-25
RU2010111551A (ru) 2011-10-10
ES2447543T3 (es) 2014-03-12
PE20090630A1 (es) 2009-05-16
EP2408761B1 (en) 2014-01-01
WO2009032124A1 (en) 2009-03-12
US20110104110A1 (en) 2011-05-05
AU2008295484A1 (en) 2009-03-12
ECSP10010004A (es) 2010-03-31

Similar Documents

Publication Publication Date Title
MX2010002317A (es) Derivados de indol sustituidos y metodos para su utilizacion.
MX2010005356A (es) Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
MX2010005355A (es) Derivados de indol sustituidos con 3-aminosulfonilo y metodos de uso de los mismos.
MX2010002316A (es) Derivados tetraciclicos de indol y su uso para el tratamiento o prevencion de infecciones virales.
MX2010002319A (es) Derivados indolicos 2,3 sustituidos para el tratamiento de infecciones virales.
TW200833684A (en) 5,6-ring annulated indole derivatives and methods of use thereof
TW200833662A (en) 4,5-ring annulated indole derivatives and methods of use thereof
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
UA100250C2 (uk) Інгібітори реплікації вірусу імунодефіциту людини
SG179488A1 (en) Virus like particle purification
WO2008127364A3 (en) Antiviral compounds and use thereof
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
CL2012001176A1 (es) Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
MY161495A (en) Virus like particle compositions and methods of use
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
MX2009011002A (es) Composiciones de proteccion de isquemia/reperfusion y metodos de uso.
MX363189B (es) Productos químicos, composiciones y métodos para tratamiento y prevención de infecciones de virus orthopox y enfermedades asociadas.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2009013828A (es) Composiciones terapeuticas y su uso.
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal